Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for improving or preventing nonalcoholic fatty liver

a technology for fatty liver and composition, applied in the direction of tripeptide ingredients, drug compositions, peptide/protein ingredients, etc., can solve the problems of increased fatty liver, increased diabetes, and increased risk of nonalcoholic steatohepatitis, so as to reduce the deposition of fat, improve the fatty liver, and suppress the development of hepatic disorders

Inactive Publication Date: 2019-05-02
KOHJIN CO LTD +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]The composition of the present invention can be used effectively in order to improve fatty liver by reducing fat deposition on the liver with respect to nonalcoholic fatty liver, and further can suppress development to hepatic disorder. Therefore, the agent for suppressing fat deposition on the liver, and the agent for improving fatty liver of the present invention further have actions of preventing or improving development to hepatic cirrhosis, hepatitis and liver cancer based on the actions described above.
[0020]The composition of the present invention can be used effectively for a patient who is in an early stage of nonalcoholic fatty liver, particularly who is in mild disease state or does not have a metabolic disorder such as high blood pressure, hyperlipidemia or impaired glucose tolerance, a patient who has low liver stiffness, and a patient who does not have disease other than fatty liver. In these cases, the present invention is also effective for a disease that is not affected with meal, exercise therapy and the like.

Problems solved by technology

Increase of diabetes, fatty liver, cancer, cardiac disease and the like as a lifestyle related disease has been problematic.
The cause is obesity, diabetes, hyperlipidemia or the like, but factors involved in the pathogenesis are diverse and there is no established therapy.
Furthermore, nonalcoholic steatohepatitis is likely to develop to hepatic cirrhosis or liver cell cancer, and thus needs more active treatment and the like.
However, it has been not known that glutathione is effective for the nonalcoholic fatty liver disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for improving or preventing nonalcoholic fatty liver
  • Composition for improving or preventing nonalcoholic fatty liver
  • Composition for improving or preventing nonalcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

example 1

(Evaluation of Efficacy for NASH / NAFLD)

[0039]To subjects (16 persons) whose meal or exercise therapy for 12 weeks or more was ineffective and who had NAFLD in 31 IU / L or more of ALT, glutathione (manufactured by KOHJIN Life Sciences Co., Ltd.) was orally administered in 300 mg per one day. Liver biopsy was performed before initiation of glutathione administration and after 16 weeks of the administration, and blood examination was performed every 4 weeks. The results are shown in Table 1.

[0040]The effects of the present invention are summarized in Table 2 with the subjects affected with the present invention (Case IDs 1 to 9) and the subjects not affected with the present invention (Case IDs 10 to 16).

TABLE 1Type IV collagenALT (IU / L)7s (ng / ml)HbA1C (%)Case IDAgeSex0 wk4 wk8 wk12 wk16 wk0 wk8 wk16 wk0 wk4 wk8 wk12 wk16 wk139M67773943484.33.94.35.25.35.15.45.3271F96353423504.94.94.93.865.966.1339F61483732433.12.93.4666.16.16.2441M96241920254.74.43.95.45.25.35.35.3545M63463138423.43.63...

example 2

[0042]Effects of the present invention were further confirmed using a mouse.

[0043]Mice (C57 / B6J, 8 weeks old male) were divided into 4 groups (5 animals each), and the first group (DB) was freely fed with ordinary food (CertifiedDiet “MF” manufactured by Oriental Yeast Co., ltd.). The second group (HFD) was freely fed with high-fat food (High Fat Diet 32, manufactured by CLEA Japan, Inc.), was freely given water only. The third group (HFD6) was freely fed with high-fat food (High Fat Diet 32, manufactured by CLEA Japan, Inc.), and glutathione was mixed with water so that glutathione can be taken by 6 mg / kg / day. The fourth group (HFD60) was freely fed with high-fat food (High Fat Diet 32, manufactured by CLEA Japan, Inc.), and glutathione was mixed with water so that glutathione can be taken by 60 mg / kg / day.

[0044]When the mouse was 20 weeks old, the body weight, the liver weight, the serum aspartate aminotransferase (AST), the alanine aminotransferase (ALT), the serum triglyceride (T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
blood pressureaaaaaaaaaa
blood pressureaaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

Description

[0001]This application is a divisional application of U.S. patent Ser. No. 15 / 555,901, filed Sep. 5, 2017, which is a U.S. national stage entry of PCT / JP2016 / 056341, filed Mar. 2, 2016, which claims priority to JP 2015-041317, filed Mar. 3, 2015. The disclosures of each of the above are hereby incorporated by reference in their entirety.TECHNICAL FIELD[0002]The present invention relates to a composition for preventing or improving nonalcoholic fatty liver in which fat is deposited on a liver in spite of the alcohol intake history of a level that a liver disease is not caused.BACKGROUND ART[0003]Increase of diabetes, fatty liver, cancer, cardiac disease and the like as a lifestyle related disease has been problematic. Fat may be deposited on the liver and cause a hepatic disorder in spite of the alcohol intake history of a level that a liver disease is not caused. The cause is obesity, diabetes, hyperlipidemia or the like, but factors involved in the pathogenesis are diverse and ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/06A61K38/00A61P1/16
CPCA61K38/063A61K38/00A61P1/16A61K38/03A61K38/06
Inventor KESSOKU, TAKAOMINAKAJIMA, ATSUSHISUMIDA, YOSHIOEGUCHI, YUICHIROSAITO, SUSUMUSAUCHI, YUSUKE
Owner KOHJIN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com